Model Medicines Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Model Medicines is a La Jolla, California-based biotechnology research company that uses AI to model chemistry and human biology to accelerate drug discovery. Founded in 2019, it sits at the intersection of data science, biology, and drug development, pursuing a pipeline of 67 validated assets in cellular disease models across 12 therapeutic targets, including oncology, virology, gastric, neurological, and weight disorders. Its customers are pharmaceutical researchers and biotech partners seeking more efficient early-stage drug discovery and translational insights. The company has pursued collaborations with academic medical centers to test antiviral potential, including partnerships with Icahn School of Medicine at Mount Sinai and UCSD, and it has highlighted a lead candidate, MDL-001, at industry events. In addition, Model Medicines launched Galileo, an AI-based drug discovery platform, in 2022 to support discovery for hematological diseases and solid tumors.